Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06259669 · ClinicalTrials.gov registry record

Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population

A clinical trial of Atopic Dermatitis and Pregnancy Related, sponsored by Incyte Corporation.

Recruiting
Registry status
958
Enrollment target
1
Study location

NCT06259669: Recruiting study of Atopic Dermatitis and Pregnancy Related, sponsored by Incyte Corporation.

NCT06259669 is a study of Atopic Dermatitis and Pregnancy Related that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 958 participants, above the 603-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (59% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06259669, a study of Atopic Dermatitis and Pregnancy Related, is actively recruiting participants, sponsored by Incyte Corporation.

RECRUITING
Registry status
958 participants
Enrollment target
1
Study location

Study Summary

This observational (enrollment into the registry while the pregnancy is ongoing) study is being conducted to compare the frequency of major congenital malformation (MCM)s among infants of women exposed to ruxolitinib cream during pregnancy with infants of women not exposed to ruxolitinib cream during pregnancy.

Primary Outcome

Defined as any major structural or chromosomal defect in live-born infants, stillbirths or spontaneous losses equal to or greater than 20 weeks' gestation, or electively terminated pregnancies of any gestational age.

Interventions

  • DRUG Ruxolitinib Cream

Study Locations (1)

North Carolina

  • Syneos Health (remote site) - Morrisville

Trial Details

FieldValue
Enrollment Target 958 participants
Start Date 2023-09-13
Est. Completion 2033-08-01
Incyte Corporation

239 total trials

What NCT06259669 shows while recruiting

NCT06259669 is an observational study that tracks outcomes without assigning an intervention. The registered 958 participants enrollment target is mid-sized for trials with a published cap, above the 603-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (59% higher).

The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Ruxolitinib Cream is the first listed.

NCT06259669 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT06259669 about?

NCT06259669 is a clinical study titled "Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population". This observational (enrollment into the registry while the pregnancy is ongoing) study is being conducted to compare the frequency of major congenital malformation (MCM)s among infants of women exposed to ruxolitinib cream during pregnancy with infants of women not exposed to ruxolitinib cream durin...

What is the current status of trial NCT06259669?

This trial is currently recruiting. The enrollment target is 958 participants. The study started on 2023-09-13. Estimated completion is 2033-08-01.

What conditions does trial NCT06259669 study?

This clinical trial studies the following conditions: Atopic Dermatitis, Pregnancy Related.

What interventions are being tested in trial NCT06259669?

The interventions under investigation include: Ruxolitinib Cream (DRUG).

Who is sponsoring clinical trial NCT06259669?

This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06259669 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Atopic Dermatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06259669's enrollment target sits among peer trials

958 13th of 150 higher than 138 of 150 other Atopic Dermatitis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04726241 · 960 participants · Phase 1

    The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • NCT05142384 · 960 participants · NA

    ICBT (Internet Based Cognitive Behavioral Therapy) for Maternal Depression: Community Implementation in Head Start

  • NCT05178498 · 960 participants

    Impact of Dietary Inflammatory Potential on Breast Cancer Risk

  • NCT05946629 · 960 participants · NA

    SELUTION 4 De Novo Small Vessel IDE Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06259669, the US trial registry maintained by the National Library of Medicine. NCT06259669 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.